Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of Staccato alprazolam for stereotypical prolonged seizures
2021-002637-42Phase 3Active
- Sponsor
- UCB
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alprazolam in status epilepticus (SE) and epilepsy, sponsored by UCB. Primary endpoint: Treatment-emergent adverse events. Started Aug 2021; status: active.
02
Drugs
alprazolam
03
Conditions
status epilepticus (SE)epilepsy
Beyond the preview
Go deeper on 2021-002637-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002637-42.